抗生素临床药理学:CKD与ESKD患者的用药考量
本文综述常用抗生素在慢性肾脏病(CKD)和终末期肾病(ESKD)患者中的治疗地位、作用机制、药代动力学与药效学。CKD可改变蛋白结合、分布容积、肾脏与非肾脏清除,需调整剂量以防毒性;不同药效学目标(如β-内酰胺类最大化游离药物高于MIC时间、氨基糖苷类最大化游离峰浓度/MIC比)对应不同调整策略。血透患者还需考虑静脉给药时机及新型透析技术对药物清除的影响。
要点
- CKD患者蛋白结合、分布容积及清除改变,需个体化调整抗生素剂量。
- 时间依赖型药物需最大化游离药物高于MIC时间,浓度依赖型需最大化游离峰/MIC比。
- 血透患者可考虑透析结束前静脉给药,并注意新型透析器增加药物清除。
核心结论
- CKD与ESKD患者使用抗生素需根据药代与药效学改变个体化调整剂量,以防毒性并保证疗效。
研究设计与样本
- 综述,讨论常用抗生素在CKD或ESKD患者中的治疗地位、作用机制、药代动力学、药效学及其他药理考量。
主要发现
- CKD可改变蛋白结合、分布容积、肾脏清除和非肾脏清除,导致需要调整抗生素剂量以预防毒性。
- 时间依赖型药物(如β-内酰胺类)需最大化游离药物浓度高于MIC的时间;浓度依赖型药物(如氨基糖苷类)需最大化游离峰浓度与MIC比值。
- 相应调整策略分别为降低剂量但维持正常给药频率,或给予正常(甚至更大)剂量但减少给药频率。
- 血透患者可倾向选择可在透析结束前静脉给药的抗生素,且新型透析技术和滤器可增加药物清除。
临床怎么用
- 处方抗生素时应结合患者药代动力学改变(如蛋白结合、分布容积、清除)和药物药效学特性进行剂量调整。
- 对时间依赖型抗生素,调整目标为延长游离药物高于MIC的时间;对浓度依赖型,调整目标为最大化游离峰/MIC比。
- 血透患者可考虑透析结束前静脉给药,并关注新型透析技术对药物清除的潜在增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antimicrobial pharmacology and its effect on prescribing is quite complex. Selecting an antibiotic that will optimally treat an infection while minimizing adverse effects and the development of resistance is only the first step, as one must also consider the patient's individual pharmacokinetic alterations and the pharmacodynamic properties of the drug when prescribing it as well. Patients with CKD may have alterations in their protein binding, volumes of distribution, kidney clearance, and nonrenal clearance that necessitates antibiotic dose adjustments to prevent the development of toxicity. Knowledge of a drug's pharmacodynamics, defined as the relationship between drug exposure and antibacterial efficacy, provides some guidance regarding the optimal way to make dose adjustments. Different pharmacodynamic goals, such as maximizing the time that free (unbound) drug concentrations spend above the minimum inhibitory concentration (MIC) for time dependent drugs (e.g., β-lactams) or maximizing the free peak-to-MIC ratio for concentration-dependent antibiotics (e.g., aminoglycosides), require different adjustment strategies; for instance, decreasing the dose while maintaining normal dosing frequency or giving normal (or even larger) doses less frequently, respectively. Patients receiving hemodialysis have other important prescribing considerations as well. The nephrologist or patient may prefer to receive antibiotics that can be administered intravenously toward the end of a dialysis session. Additionally, newer dialysis technologies and filters can increase drug removal more than originally reported. This review will discuss the place in therapy, mechanism of action, pharmacokinetic, pharmacodynamic, and other pharmacologic considerations encountered when prescribing commonly used antibiotics in patients with chronic kidney disease or ESKD.
引用
- Eyler RF, Shvets K. Clinical Pharmacology of Antibiotics. Clin J Am Soc Nephrol. 2019. PMID: 30862698. doi:10.2215/CJN.08140718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。